Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

Next Previous
X
Search
Trial Profile

A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 13 Apr 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TOPAZ
  • Sponsors Sanofi Genzyme

    • Most Recent Events

    • 15 Oct 2021 Results of an analysis assessing the efficacy and safety of alemtuzumab in CARE-MS I patients over 10 years presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 15 Oct 2021 Results assessing the efficacy and safety of alemtuzumab in CARE-MS II patients over 10 year, presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 23 Dec 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top